DNA Script vs Pliant Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
DNA Script has raised $335M total including a $165M oversubscribed Series C; received CE Mark in 2025 for SYNTAX System in clinical labs across Europe; developing enzymatic DNA synthesis printers that enable on-demand, benchtop DNA production for.
About
DNA Script is a biotechnology company founded in 2014 and headquartered in Paris, France (with US operations in South San Francisco), that has developed a breakthrough enzymatic DNA synthesis (EDS) platform. Traditional chemical-based DNA synthesis — the process of producing custom DNA sequences used in genomics, synthetic biology, diagnostics, and therapeutic development — relies on hazardous chemicals and generates significant toxic waste. DNA Script's approach replaces these chemicals with enzymes (specifically terminal deoxynucleotidyl transferase, or TdT), enabling faster, greener, and more scalable DNA production at the benchtop.
Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.
About
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.